so basically bisantrene API would be open to use as a generic, but retaining the crystallisation issues. what you are suggesting is some very smart chemists could also resolve the crystallisation and thus effective make an RC220. But if the manufacturing process required to prevent crystallisation is also subject of a patent, then they would need to not only reformulate but also come up with a manufacture work around (which makes it extremely difficult). It seems all too hard, don't generics simply want to copy and sell?
Cardioprotection thread, page-832
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
0.010(0.65%) |
Mkt cap ! $265.8M | |||
| Open | High | Low | Value | Volume |
| $1.55 | $1.56 | $1.51 | $95.69K | 62.25K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3015 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 4018 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |